Can analysts adopt a bullish outlook for Horizon Pharma Public Limited Company (NASDAQ:HZNP)?

February 15, 2018 - By Maria Brooks

 Can analysts adopt a bullish outlook for Horizon Pharma Public Limited Company (NASDAQ:HZNP)?
Investors sentiment increased to 1 in 2017 Q3. Its up 0.08, from 0.92 in 2017Q2. It improved, as 33 investors sold Horizon Pharma Public Limited Company shares while 50 reduced holdings. 28 funds opened positions while 55 raised stakes. 132.29 million shares or 1.03% more from 130.94 million shares in 2017Q2 were reported.
Great Lakes Advsr Limited Liability Corporation has 556,229 shares. Hl Fincl Services Llc reported 0% stake. California Public Employees Retirement Sys holds 0.01% or 325,085 shares. Wells Fargo & Mn accumulated 456,169 shares. Jw Asset Ltd Co stated it has 2.51% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Principal Financial Group reported 399,132 shares. Point72 Asset Lp holds 0.16% or 2.81 million shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has 5,210 shares. Illinois-based Css Limited Company Il has invested 0.02% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Susquehanna Group Limited Liability Partnership stated it has 543,431 shares. Fmr Ltd holds 0% or 776,496 shares. Vanguard Gru reported 13.18 million shares. Pnc Fincl Inc reported 1,000 shares or 0% of all its holdings. Prudential owns 77,390 shares for 0% of their portfolio. Advisory Svcs Net Limited Liability Corp holds 0% or 289 shares.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Horizon Pharma had 55 analyst reports since September 9, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 25 by Piper Jaffray. Brean Capital downgraded it to “Hold” rating and $40 target in Tuesday, September 22 report. The firm earned “Buy” rating on Sunday, July 30 by Cantor Fitzgerald. The rating was initiated by Jefferies on Tuesday, January 19 with “Buy”. The company was maintained on Tuesday, August 8 by Jefferies. Mizuho maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) on Tuesday, May 10 with “Buy” rating. The stock has “Buy” rating by Citigroup on Monday, November 28. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) has “Buy” rating given on Tuesday, February 28 by Mizuho. Mizuho upgraded Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Friday, December 16. Mizuho has “Buy” rating and $25 target. The firm earned “Buy” rating on Friday, October 20 by Stifel Nicolaus. Below is a list of Horizon Pharma Public Limited Company (NASDAQ:HZNP) latest ratings and price target changes.

30/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $20.0 Maintain
12/01/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
30/11/2017 Broker: UBS Rating: Buy New Target: $20.0 Maintain
10/11/2017 Broker: Cowen & Co Rating: Buy New Target: $22.0 Maintain
07/11/2017 Broker: Jefferies Rating: Buy Old Target: $16 New Target: $21 Maintain
06/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $17.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $18.0 Maintain
20/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20.0 Maintain
13/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $18.0 Maintain
13/10/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain

The stock decreased 0.50% or $0.07 during the last trading session, reaching $14.04. About 538,615 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 28.13% since February 15, 2017 and is downtrending. It has underperformed by 44.83% the S&P500.

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company has market cap of $2.30 billion. The companyÂ’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. It currently has negative earnings. The Company’s products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Reuters.com which released: “Horizon Pharma weighs sale of primary care unit -sources” on September 15, 2017, also Seekingalpha.com with their article: “Horizon Pharma: Primary Care Segment Remains A Burden And Should Be Sold” published on December 20, 2017, Fool.com published: “Why Horizon Pharma plc Stock Is Crashing Today” on May 08, 2017. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Globenewswire.com and their article: “Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial …” published on January 29, 2018 as well as Seekingalpha.com‘s news article titled: “Horizon Pharma Plc (HZNP) Q2 2017 Results – Earnings Call Transcript” with publication date: August 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.